Nobiletin suppresses cell viability through AKT Pathways in PC-3 and DU-145 prostate cancer cells

被引:44
作者
Chen, Jianchu [1 ,2 ]
Creed, Ashley [2 ]
Chen, Allen Y. [3 ]
Huang, Haizhi [1 ,2 ]
Li, Zhaoliang [2 ]
Rankin, Gary O. [4 ]
Ye, Xingqian [1 ]
Xu, Guihua [1 ]
Chen, Yi Charlie [2 ]
机构
[1] Zhejiang Univ, Coll Biosyst Engn & Food Sci, Fuli Inst Food Sci, Zhejiang Key Lab Agrofood Proc, Hangzhou 310058, Zhejiang, Peoples R China
[2] Alderson Broaddus Univ, Coll Sci Technol & Math, Philippi, WV 26416 USA
[3] W Virginia Univ, Dept Pharmaceut Sci, Morgantown, WV 26506 USA
[4] Marshall Univ, Joan C Edwards Sch Med, Dept Pharmacol Physiol & Toxicol, Huntington, WV 25755 USA
基金
美国国家科学基金会;
关键词
Nobiletin; Prostate cancer; VEGF; NF-kappa B; HIF-1; alpha; cMyc; NF-KAPPA-B; CITRUS NOBILETIN; OVARIAN-CANCER; TUMOR-CELLS; FLAVONOIDS; RISK; ANGIOGENESIS; METASTASIS; ACTIVATION; MECHANISMS;
D O I
10.1186/2050-6511-15-59
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Nobiletin is a non-toxic dietary flavonoid that possesses anti-cancer properties. Nobiletin has been reported to reduce the risk of prostate cancer, but the mechanism is not well understood. In this study, we investigated the effects of nobiletin in prostate cancer cell lines PC-3 and DU-145. Methods: Nobiletin was isolated from a polymethoxy flavonoid mixture using HPLC, cell viability was analyzed with MTS-based assays. Protein expression was examined by ELISA and western blotting. Gene expression was examined by luciferase assay. And the pathways were examined by manipulating genetic components with plasmid transfection. Results: Data showed that nobiletin decreased cell viability in both prostate cell lines, with a greater reduction in viability in PC-3 cells. HIF-1 alpha expression and AKT phosphorylation were decreased in both cell lines. The VEGF expression was inhibited in PC-3 but not DU-145 cells. cMyc expression was decreased in DU-145 cells. Nobiletin down-regulated NF-kappa B (p50) expression in nuclei of DU145 cells but not whole cells. It also suppressed NF-kappa B expression in both whole cells and nuclei of PC-3 cells. Increasing HIF-1a levels reversed nobiletin's inhibitory effects on VEGF expression, and up-regulating AKT levels reversed its inhibitory effects on HIF-1a expression. We speculate that AKT influences cell viability probably by its effect on NF-kappa B in both prostate cells. The effect of nobiletin on VEGF expression in PC-3 cell lines was through the AKT/HIF-1 alpha pathway. Conclusion: Taken together, our results show that nobiletin suppresses cell viability through AKT pathways, with a more profound effect against the more metastatic PC-3 line. Due to this enhanced action against a more malignant cell type, nobiletin may be used to improve prostate cancer survival rates.
引用
收藏
页数:10
相关论文
共 31 条
[1]   Nuclear factor-κ-B:: The enemy within [J].
Aggarwal, BB .
CANCER CELL, 2004, 6 (03) :203-208
[2]   A Convenient and Safe O-Methylation of Flavonoids with Dimethyl Carbonate (DMC) [J].
Bernini, Roberta ;
Crisante, Fernanda ;
Ginnasi, Maria Cristina .
MOLECULES, 2011, 16 (02) :1418-1425
[3]   Nuclear factor-kappa B and cancer: its role in prevention and therapy [J].
Bharti, AC ;
Aggarwal, BB .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :883-888
[4]  
Bosland M C, 2000, J Natl Cancer Inst Monogr, P39
[5]  
Chu EC, 2004, MED SCI MONITOR, V10, pRA235
[6]   Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer [J].
Crawford, E. David .
UROLOGY, 2009, 73 (5A) :4-10
[7]   Epidemiology of prostate cancer [J].
Crawford, ED .
UROLOGY, 2003, 62 (6A) :3-12
[8]   Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells [J].
Fang, Jing ;
Zhou, Qiong ;
Shi, Xiang-lin ;
Jiang, Bing-hua .
CARCINOGENESIS, 2007, 28 (03) :713-723
[9]   Flavonoid intake and ovarian cancer risk in a population-based case-control study [J].
Gates, Margaret A. ;
Vitonis, Allison F. ;
Tworoger, Shelley S. ;
Rosner, Bernard ;
Titus-Ernstow, Linda ;
Hankinson, Susan E. ;
Cramer, Daniel W. .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (08) :1918-1925
[10]   Introduction to NF-κB:: players, pathways, perspectives [J].
Gilmore, T. D. .
ONCOGENE, 2006, 25 (51) :6680-6684